MedTrace Logo

Evaluation of AMG 714 for Vitiligo

NCT04338581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-21

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.

Conditions

Interventions

BIOLOGICAL

AMG 714

anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)

BIOLOGICAL

Placebo

Placebo for AMG 714

PROCEDURE

nbUVB phototherapy

Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.

Sponsors & Collaborators

  • Immune Tolerance Network (ITN)

    collaborator NETWORK

  • PPD Development, LP

    collaborator INDUSTRY

  • Rho Federal Systems Division, Inc.

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Brett A. King, MD, PhD · Yale University School of Medicine: Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2024-10-16
Completion
2025-04-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338581 on ClinicalTrials.gov